Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

P

Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Andersen JW, Chesney MA. "Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084." AIDS Patient Care STDS. 2008;22(1):29-40.
Cohen MS, Chen YQ, McCauley M, et al. "Prevention of HIV-1 infection with early antiretroviral therapy." N. Engl. J. Med.. 2011;365(6):493-505.
Dykes C, A Mukherjee L, Bosch RJ, Connick E, Volberding PA, Demeter LM. "Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371." J. Acquir. Immune Defic. Syndr.. 2010;55(1):132-4.
Shivakoti R, Christian P, Yang W-T, et al. "Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults." Clin Nutr. 2016;35(1):183-9.
Fife KH, Wu JW, Squires KE, D Watts H, Andersen JW, Brown DR. "Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2009;51(3):274-82.
Robertson KR, Smurzynski M, Parsons TD, et al. "The prevalence and incidence of neurocognitive impairment in the HAART era." AIDS. 2007;21(14):1915-21.
Kalayjian RC, Machekano RN, Rizk N, et al. "Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy." J. Infect. Dis.. 2010;201(12):1796-805.
Kantor R, Smeaton L, Vardhanabhuti S, et al. "Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial." Clin. Infect. Dis.. 2015;60(10):1541-9.
Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA. "Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2007;44(3):268-77.
Orlov M, Smeaton LM, Kumwenda J, Hosseinipour MC, Campbell TB, Schooley RT. "Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population." PLoS ONE. 2015;10(6):e0129519.
Stringer EM, Kendall MA, Lockman S, et al. "Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy." PLoS ONE. 2018;13(7):e0199555.
Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. "Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects." J. Infect. Dis.. 2008;197(6):867-70.
Paredes R, Lalama CM, Ribaudo HJ, et al. "Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure." J. Infect. Dis.. 2010;201(5):662-71.
Asmelash A, Zheng Y, Kaloustian KWools, et al. "Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa." BMC Infect. Dis.. 2014;14:331.
Zheng L, Bosch RJ, Chan ES, et al. "Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy." Antivir. Ther. (Lond.). 2013;18(1):39-43.
Singini I, Campbell TB, Smeaton LM, et al. "Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy." HIV Clin Trials. 2016:1-8.
Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. "Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999)." J. Acquir. Immune Defic. Syndr.. 2006;43(3):320-3.
Mugavero MJ, Pence BWells, Whetten K, et al. "Predictors of AIDS-related morbidity and mortality in a southern U.S. Cohort." AIDS Patient Care STDS. 2007;21(9):681-90.
Crump JA, Wu X, Kendall MA, et al. "Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study." BMC Infect. Dis.. 2015;15:12.
Eron JJ, Park J-G, Haubrich R, et al. "Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy." Antimicrob. Agents Chemother.. 2009;53(6):2335-41.
Rutstein SE, Hosseinipour MC, Weinberger M, et al. "Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm." BMC Infect. Dis.. 2016;16(1):280.
Balagopal A, Asmuth DM, Yang W-T, et al. "Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study." J. Acquir. Immune Defic. Syndr.. 2015;70(2):163-71.
Shivakoti R, Gupte N, Yang W-T, et al. "Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy." Nutrients. 2014;6(11):5061-78.
Schackman BR, Scott CA, Sax PE, et al. "Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial." Clin. Infect. Dis.. 2007;45(8):1062-70.
Abbas UL, Anderson RM, Mellors JW. "Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings." J. Acquir. Immune Defic. Syndr.. 2006;41(5):632-41.
Sha BE, Tierney C, Cohn SE, et al. "Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150." HIV Clin Trials. 2011;12(1):9-23.
Hennig S, Svensson EM, Niebecker R, et al. "Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs." J. Antimicrob. Chemother.. 2016;71(5):1330-40.
Makita-Chingombe F, Kutscher HL, DiTursi SL, Morse GD, Maponga CC. "Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations." J Drug Deliv. 2016;2016:3810175.
Sherman KE, Rouster SD, Kang M, Umbleja T, Sterling R, Butt AA. "PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals." Dig. Dis. Sci.. 2018.
Jiang W, Lederman MM, Hunt P, et al. "Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection." J. Infect. Dis.. 2009;199(8):1177-85.

Pages